Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dara BioSciences and Innocutis Holdings have signed an exclusive agreement to commercialize Bionect (hyaluronic acid sodium salt, 0.2%) within the oncology and radiation oncology marketplace.
Subscribe to our email newsletter
FDA-approved Bionect is indicated for the management of irritation of the skin as well as first and second degree burns, and is currently being promoted and sold by Innocutis in the dermatology market.
Dara president and chief executive officer David J. Drutz said the agreement with Innocutis for rights to commercialize Bionect shows the conmpany’s ability to execute on its strategic plan for adding cancer and cancer-support products through ongoing licensing efforts.
Dara has obtained US commercializing rights to launch Bionect in the second quarter of this year.
Dara BioSciences is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment